Population
Patients with nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome
Design
Review
Authors
Loading...
May support insulin-sensitizing agents in NAFLD; leaves open need for RCTs to confirm benefit.
This review highlights insulin resistance as a central mechanism in NAFLD and metabolic syndrome, suggesting a therapeutic role for insulin-sensitizing agents.
Bugianesi et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: